Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Nutr Neurosci. 2024 Oct;27(10):1077-1087. doi: 10.1080/1028415X.2023.2301163. Epub 2024 Feb 14.
Brain tissue in Alzheimer's patients is exposed to oxidative stress. Silymarin is an adjunct drug that has anti-inflammatory and antioxidant properties.
This study aimed to evaluate the effect of silymarin on biomarkers of oxidative stress, inflammation, and disease severity in Alzheimer's patients.
This randomized, single-blind clinical trial study was performed on 33 patients with Alzheimer's disease (AD) whose disease was confirmed by DSM-5 criteria and by brain imaging. Patients in the case group received three 250 mg silymarin capsules daily (each containing 150 mg silymarin), as an adjunctive medication in addition to the routine medication regimen. In the placebo group (control), patients received the same amount of placebo. All patients underwent Mini Mental State Exam (MMSE) and a panel of blood tests including malondialdehyde, neopterin, catalase, paraoxonase-1, total oxidative status, and total antioxidant capacity to reevaluate the changes pre/postintervention at the end of the trimester.
The catalase and MDA serum levels after the adjunctive silymarin treatment decreased significantly (Catalase= 9.29 ± 7.02 vs Catalase= 5.32 ± 2.97, = 0.007 and MDA= 4.29 ± 1.90 vs MDA= 1.66 ± 0.84, < 0.001) while MMSE increased notably (MMSE= 10.39 ± 6.42 vs MMSE= 13.37 ± 6.81, < 0.001).
Silymarin can be effective as an adjunct drug and a powerful antioxidant in reducing oxidative stress and improving the course of AD.
阿尔茨海默病患者的脑组织会受到氧化应激的影响。水飞蓟素是一种具有抗炎和抗氧化特性的辅助药物。
本研究旨在评估水飞蓟素对阿尔茨海默病患者氧化应激、炎症和疾病严重程度生物标志物的影响。
这是一项随机、单盲临床试验研究，纳入了 33 名经 DSM-5 标准和脑部影像学检查确诊为阿尔茨海默病（AD）的患者。病例组患者每日服用 3 粒 250mg 的水飞蓟素胶囊（每粒含 150mg 水飞蓟素），作为常规治疗方案的辅助药物。在安慰剂组（对照组）中，患者服用相同剂量的安慰剂。所有患者均接受了简易精神状态检查（MMSE）和一系列血液检查，包括丙二醛、新蝶呤、过氧化氢酶、对氧磷酶-1、总氧化状态和总抗氧化能力，以在干预结束时再次评估 trimester 结束前后的变化。
在接受水飞蓟素辅助治疗后，血清过氧化氢酶和 MDA 水平显著下降（过氧化氢酶=9.29±7.02 比过氧化氢酶=5.32±2.97，=0.007 和 MDA=4.29±1.90 比 MDA=1.66±0.84， < 0.001），而 MMSE 明显提高（MMSE=10.39±6.42 比 MMSE=13.37±6.81， < 0.001）。
水飞蓟素可作为一种有效的辅助药物和强大的抗氧化剂，降低氧化应激，改善 AD 患者的病程。
